Holen Sie sich die Stockscreener-App
3.89
0.28%
-0.011
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Zacks Small Cap Issues Negative Forecast for ENSC Earnings - Defense World
Ensysce Biosciences (ENSC) Projected to Post Earnings on Friday - Defense World
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - EIN News
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Ensysce Biosciences, Inc. SEC 10-K Report - TradingView
Ensysce Biosciences Narrows Losses to $8M, Secures FDA Breakthrough Status - StockTitan
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
(ENSC) Long Term Investment Analysis - Stock Traders Daily
Ensysce Biosciences to Present Pain Management Innovations at ROTH Conference - StockTitan
Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids - Marketscreener.com
How Ensysce's FDA Fast-Tracked Opioids Could Transform Pain Management Safety - StockTitan
Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website - ACCESS Newswire
Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results - ACCESS Newswire
Ensysce Biosciences Regains Compliance with Nasdaq - ACCESS Newswire
Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering - ACCESS Newswire
How To Trade (ENSC) - Stock Traders Daily
Revolutionary Pain Management: This New Opioid Actually Prevents Overdose - StockTitan
Ensysce Biosciences Announces Fourth Quarter and Full Year 2021 Earnings Release Date and Timing of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic - ACCESS Newswire
Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium - ACCESS Newswire
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - ACCESS Newswire
Ensysce Biosciences Releases Updated Investor Presentation Ahead of Corporate Update Call - ACCESS Newswire
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics Summit - ACCESS Newswire
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate - ACCESS Newswire
Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection - ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR - NEWSnet
Ensysce reports overdose protection in drug trial - Investing.com
Ensysce's PF614-MPAR Shows Breakthrough Overdose Protection in Phase 1b Opioid Trial - StockTitan
Biotech Steals The Show Following $14 Million Grant Announcement - MSN
Ensysce's Breakthrough Pain Drug Gets FDA Special Status; Secures $23.7M Funding Boost - StockTitan
Ensysce Biosciences (NASDAQ:ENSC) Shares Down 5.6% – Should You Sell? - Defense World
Ensysce Biosciences Regains Full Compliance with Nasdaq - Financial Content
Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection Drug Development - StockTitan
983,518 Shares in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Bought by Anson Funds Management LP - MarketBeat
ENSC Stock Touches 52-Week High at $7.24 Amid Market Volatility - Investing.com Nigeria
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study - Marketscreener.com
Revolutionizing Pain Relief: The next generation of opioids | Interview with Ensysce Biosciences CEO - Marketscreener.com
Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study - Marketscreener.com
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic - Marketscreener.com
Ensysce Biosciences, Inc. Submits Phase 3 Protocol to the FDA - Marketscreener.com
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR - Marketscreener.com
Ensysce Biosciences, Inc. Announces Strategic Partnership for the Development and Commercial Launch of Pf614 and Pf614-Mpar - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Renewal of Collaboration with Quotient Sciences to Undertake the Study PF614-MPAR-102 to Examine and Evaluate the Full Commercial Dose Range of the PF614-MPAR Drug Product - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):